All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Molecular Cancer

Sign up for email alert when new content gets added: Sign up

Mohammadhassan Arjmand, PhD1,2 and Farnaz Zahedi Avval, MD1,3*
 
1 Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran
2 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
 
*Correspondence: Farnaz Zahedi Avval, MD, Department of Clinical Biochemistry, Faculty of Medicine, Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran, Tel: +98 51 38002365, Email: [email protected]

Received Date: Dec 09, 2018 / Accepted Date: Dec 26, 2018 / Published Date: Jan 12, 2019

Citation: Arjmand M, Zahedi Avval F. Clinical biomarkers for detection of ovarian cancer. J Mol Cancer. 2019;2(1):3-7.

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [email protected]

Abstract

Between all of the gynecological cancers, ovarian cancer (OvCa) shows high clinical challenge because it is difficult to be detected in early stage and it has the highest mortality proportional to the other gynecologic malignancies. Despite medical advances and the development of diagnostic tools such as biomarkers and detection techniques, OvCa remains a fatal cancer with high progression. There are different types of OvCa based on histological classification; Epithelial Ovarian Cancer (EOC) is the most common, whereas, stromal and germ cell tumors are of lower abundance. EOC is identified in over 80% of women at late-stage with complications include the spread of tumor implants throughout the peritoneal cavity. Early diagnosis of OvCa is helpful in the treatment and promotion of survival rate. Such diagnostic medical methods and biomarkers include vaginal and pelvic examination, diagnostic imaging, serum CA125, and screening tests or a combination used in medical centers, however, it is necessary to find new biomarkers with long-term stability and high specificity and sensitivity to detect OvCa in early stages of disease. This review presents novel and robust biomarkers and methods for detecting OvCa.

Keywords

Ovarian Cancer; Serum and genetic Biomarkers; Early diagnosis

 

Recommended Conferences

2nd World Congress on Cancer Science and Therapy

Barcelona, Spain

3rd World congress on Breast Cancer

Barcelona, Spain
Top